Copenhagen, Denmark, 2011-01-12 13:29 CET (GLOBE NEWSWIRE) --Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression
analysis products, today announced the launch of the 2nd generation of miRCURY
LNA™ microRNA Inhibitor libraries for genome-wide screening of microRNA
function in human and mouse. Several libraries have already been shipped to the
first customers.

The new human microRNA inhibitor library targets almost 1,000 different
microRNAs which makes it the library with the highest coverage on the market.
The human library also targets 40 proprietary miRPlus™ microRNAs. The new mouse
library likewise has the highest coverage as it targets more than 700
microRNAs.

“By use of our proprietary LNA™ technology we have been able to design highly
potent microRNA inhibitors with uniform and specific affinity for their targets
which is critical for successful high throughput screenings”, said Vice
President Sales & Marketing, Dr. Henrik M. Pfundheller and added: “Due to the
high potency caused by the high affinity and biostability of the LNA™, the
microRNA inhibitors may be applied at very low concentrations minimizing
problems with secondary effects”.

Information about the miRCURY LNA™ microRNA Inhibitor products is available at
Exiqon's website:
http://www.exiqon.com/mirna-inhibitor

Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090
2106)

See the full release in the attached PDF or at www.exiqon.com/investor/portal

PressRelease_InhibitorLibrary_110112.pdf